Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation - Hardcover

 
9780124375512: Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation
Hardcover
ISBN 10: 0124375510 ISBN 13: 9780124375512
Verlag: Academic Press, 2002

Inhaltsangabe

The Second Edition of Gene Therapy of Cancer provides crucial updates on the basic science and ongoing research in this field, examining the state of the art technology in gene therapy and its therapeutic applications to the treatment of cancer. The clinical chapters are improved to include new areas of research and more successful trials. Chapters emphasize the scientific basis of gene therapy using immune, oncogene, antisense, pro-drug activating, and drug resistance gene targets, while other chapters discuss therapeutic approaches and clinical applications. This book is a valuable reference for anyone needing to stay abreast of the latest advances in gene therapy treatment for cancer.

Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.

Über die Autorinnen und Autoren

Stanton L Gerson is Director of the Case Comprehensive Cancer Center & the National Center for Regenerative Medicine at Case Western Reserve University and Director of University Hospitals Seidman Cancer Center in Cleveland. Dr. Gerson studies DNA repair, stem cells and cancer therapy. He showed that over-expression of the MGMT DNA repair gene could prevent cancer and that a mutant form of MGMT protects hematopoietic stem cells from chemotherapy using lentiviral gene therapy. He has interrogated MGMT, MMR and BER DNA repair pathways as targets for cancer therapy, and proposed that methoxyamine would block base excision repair used in combination with chemotherapy. Dr. Gerson also directed the initial use of mesenchymal stem cells (MSCs) in bone marrow transplantation & in gene therapy.

Edmund C. Lattime is Professor of Surgery at the Robert Wood Johnson Medical School and Deputy Director, The Cancer Institute of New Jersey. Dr. Lattime studies tumor immunology and immunotherapy focusing on the tumor-host interaction and the tumor microenvironment. While faculty at Sloan Kettering and then Thomas Jefferson University, his translational studies led to the development and Phase I testing of a novel Vaccinia-GMCSF construct designed to enhance the development of antitumor immunity via infection/transfection of the tumor microenvironment. Based on his mechanistic studies of immune escape mechanisms, his group recently developed and is testing a poxvirus-based immunization strategy, which uses antigen encoding poxvirus delivered to the tumor microenvironment, in patients with locally-advanced pancreatic cancer.

Stanton L. Gerson received his M.D. at Harvard Medical School. He was a Resident in Medicine at the Hospital of the University of Pennsylvania, where he became a Fellow in Hematology-Oncology in 1980. He is an Edward Mallinckrodt Jr. Foundation Scholar, and is currently Chief, Division of Hematology/Oncology at Case Western Reserve Univeristy, where he has served since 1983. Dr. Gerson is a member of several major professional and scientific societies and is a principal investigator of funded grants for several philanthropic organizations. He is author or a contributor to over 200 research papers, abstracts, theses and book chapters. Since 1987, Dr. Gerson has been invited to be a guest lecturer at over 40 national and international conferences.

Von der hinteren Coverseite

Gene Therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of new therapeutic approaches. The Second Edition of Gene Therapy of Cancer provides crucial updates on the basic and applied sciences of gene therapy. This volume offers a comprehensive assessment of the field including the areas of immunotherapy, suicide gene therapy, oncogene and suppressor gene targeting, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive.

Key Features
* Provides in-depth description of targeted systems and treatment strategies
* Explains the underlying cancer biology necessary for understanding proposed therapeutic approaches
* Provides detailed illustrations of vector and therapeutic approaches ideal for classroom presentations and general reference
* Divided into sections including:
* Vectors for Gene Therapy of Cancer
* Immune Targeted Gene Therapy
* Oncogene-Targeted Gene Therapy
* Manupulation of Drug Resistance Mechanisms by Gene Therapy
* Anti-Angiogenesis and Pro-Apoptotic Gene Therapy
* Prodrug Activation Strategies of Gene Therapy of Cancer

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

Verlag
Academic Press
Erscheinungsdatum
2002
Sprache
Englisch
ISBN 10 
0124375510
ISBN 13 
9780124375512
Einband
Gebundene Ausgabe
Auflage
2
Anzahl der Seiten
534
Herausgeber
Gerson MD Stanton L., Lattime Edmund C., Gerson Stanton L.
Kontakt zum Hersteller
Nicht verfügbar
Verantwortliche Person
eVatmaster Consulting GmbH
497000000000
contact@evatmaster.com

Bettinastr. 30,60325
Frankfurt am Main
60325
Deutschland